Skip to main content
SpringerLink
Log in

The Role of Oral Etoposide in Non-Small Cell Lung Cancer

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral etoposide has been tested alone and in combination in a number of tumour types since the late 1980s because of its mild toxicity, high response rates, ease of administration, and comparatively low cost. Encouraging early results with protracted oral etoposide therapy in small cell lung cancer have not been borne out in non-small cell lung cancer (NSCLC), particularly in the advanced-disease setting. However, in stage IV NSCLC, oral etoposide does appear to be as compatible with most of the newer agents as it has been with platinum compounds; these combinations continue to be explored, although they have not penetrated into standard usage. In stage III NSCLC, large combined-modality studies are ongoing. Other investigations examining protracted administration in combination with radiation ‘sensitisers’ are planned. It is possible that by exploiting the ‘radiosensitising effect’ of prolonged low dose oral etoposide, combined with that of other proven radiosensitisers such as paclitaxel, gemcitabine, and topotecan, we may identify a niche for oral etoposide in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide — a phase I trial. J Clin Oncol 1989; 7: 396–401

    PubMed  CAS  Google Scholar 

  2. De Vore R, Hainsworth J, Greco FA, et al. Chronic oral etoposide in the treatment of lung cancer. Semin Oncol 1992; 19 Suppl. 14: 28–35

    Google Scholar 

  3. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374–7

    PubMed  CAS  Google Scholar 

  4. Schabel FM Jr, Trader MW, Laster WK, et al. Cis-dichloro-diammineplatinum (II): combination chemotherapy and cross-resistance with tumors of mice. Cancer Treat Rep 1979; 63: 1459–73

    PubMed  CAS  Google Scholar 

  5. Cavalli F, Sonntag RW, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 1978; 62: 473–5

    PubMed  CAS  Google Scholar 

  6. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–40

    PubMed  CAS  Google Scholar 

  7. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multi-centre randomised trial. Lancet 1996; 348: 563–6

    Article  Google Scholar 

  8. Roth JA, Johnson DH, Greco FA, et al. A Phase III trial of etoposide and cisplatin vs cyclophosphamide, doxorubicin, and vincristine vs alternation of the 2 therapies for patients with extensive small cell lung cancer: preliminary results. Proc Am Soc Clin Oncol 1989; 8: 225A

    Google Scholar 

  9. Belani CP, Doyle LA, Aisner J. Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 1994; 34 Suppl.: S118–26

    Article  PubMed  Google Scholar 

  10. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40

    Article  PubMed  CAS  Google Scholar 

  11. Johnson DH, Hainsworth JD, Hande KR, et al. Current status of etoposide in the management of small cell lung cancer. Cancer 1991; 67: Suppl.: 231–44

    Article  PubMed  CAS  Google Scholar 

  12. Loehrer PJ Sr. Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group. Semin Oncol 1992; 19 Suppl. 14: 48–52

    PubMed  Google Scholar 

  13. Non-small-cell lung cancer. Treatment/Health professionals [online]. PDQ, National Cancer Institute. Available from: http://cancernet.nci.nih.gov/clinpdg/soa/Nonsmall_cell_lung_cancer_Physician.html [Accessed 1998 Dec]

  14. Miller AA, Niell HB, Griffin JP. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 1995; 12: 59–65

    Article  PubMed  CAS  Google Scholar 

  15. Planting A, Kho S, van der Burg M, et al. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 347–52

    Article  PubMed  CAS  Google Scholar 

  16. Frasci G, Perillo G, Cornelia G, et al. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer. Cancer 1995; 75: 1578–85

    Article  PubMed  CAS  Google Scholar 

  17. Bakowski MT, Crouch JC. Chemotherapy of non-small cell lung cancer: a reappraisal and look to the future. Cancer Treat Rev 1983; 10: 159–72

    Article  PubMed  CAS  Google Scholar 

  18. Saxman S, Loehrer PJ Sr, Logie K, et al. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Invest New Drugs 1991; 9: 253–6

    Article  PubMed  CAS  Google Scholar 

  19. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992; 10: 292–6

    PubMed  CAS  Google Scholar 

  20. Blumenreich MS, Sheth SP, Miller CL, et al. Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer. Am J Clin Oncol 1994; 17: 163–5

    Article  PubMed  CAS  Google Scholar 

  21. Estapé J, Palombo H, Sanchez-Lloret J, et al. Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 1992; 28A: 835–7

    Article  PubMed  Google Scholar 

  22. Gatzemeier C, Neuhauss R, Kecmayr M. Single agent oral etoposide in advanced NSCLC (chronic daily) and in elderly patients with SCLC. Lung Cancer 1991; 7 Suppl.: 102

    Article  Google Scholar 

  23. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4: 702–9

    PubMed  CAS  Google Scholar 

  24. Comis RL, Friedland DM. New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Lung Cancer 1995; 12 Suppl.: S63–99

    Article  PubMed  Google Scholar 

  25. Grunberg SM, Crowley J, Livingston R, et al. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 1598–601

    PubMed  CAS  Google Scholar 

  26. Gracia JM, Fernandez R, Cueva J, et al. A phase II trial with oral etoposide (VP-16) and weekly cisplatin (CDDP) in non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 Suppl. 1: 128A

    Article  Google Scholar 

  27. Williamson SK, Taylor SA, Stephens RL, et al. Pilot phase II and toxicity trial of ifosfamide (IFF)/Mesna (M), protracted oral etoposide (VP) and cisplatinum (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 Suppl. 1: 120A

    Article  Google Scholar 

  28. Planting AS, van der Burg MEI, de Boer-Dennert M, et al. Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Ann Oncol 1995; 6: 190–2

    PubMed  CAS  Google Scholar 

  29. Johnson DH, De Vore R, Greco FA, et al. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Semin Oncol 1992; Suppl. 2: 50–6

    Google Scholar 

  30. Jeremic B, Shibamoto Y, Acimovic L, et al. Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial. Lung Cancer 1997; 18: 179–88

    Article  PubMed  CAS  Google Scholar 

  31. Jeremic B, Acimovic L, Mijatovic L. Carboplatin and etoposide in advanced colorectal carcinoma. A phase JJ study. Cancer 1993; 71: 2706–8

    CAS  Google Scholar 

  32. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase JJ study. J Clin Oncol 1992; 10: 1074–7

    PubMed  CAS  Google Scholar 

  33. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 1996; 14: 1055–64

    PubMed  CAS  Google Scholar 

  34. Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 1997; 38: 149–55

    Article  PubMed  CAS  Google Scholar 

  35. Ruckdeschel J. Future directions in the management of non-small cell lung cancer: a continuing perspective. Lung Cancer 1997; 18 Suppl. 2: 151

    Article  Google Scholar 

  36. Boyer MJ, Zalcberg J, Olver IN, et al. Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer. Ann Oncol 1997; 8: 485–9

    Article  PubMed  CAS  Google Scholar 

  37. Lopez JO, Federico C. Navelbine, oral etoposide, in advanced non-small cell lung cancer. Lung Cancer 1997; 18 Suppl. 1: 29A

    Article  Google Scholar 

  38. Herben VM, ten Bokkel Huinink WW, Dubbelman AC, et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997; 76: 1500–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MCP Hahnemann University, Philadelphia, Pennsylvania, USA

    Robert L. Comis (Director), David M. Friedland & Barbara C. Good

  2. Clinical Trials Research Center, Hahnemann University, 2115 South Street, MCP 30, Philadelphia, PA, 19146, USA

    Robert L. Comis (Director), David M. Friedland & Barbara C. Good

Authors
  1. Robert L. Comis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Friedland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara C. Good
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Comis, R.L., Friedland, D.M. & Good, B.C. The Role of Oral Etoposide in Non-Small Cell Lung Cancer. Drugs 58 (Suppl 3), 21–30 (1999). https://doi.org/10.2165/00003495-199958003-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00004

Keywords

Search

Navigation